Navigation Links
CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation
Date:4/15/2011

ATLANTA and IRVINE, Calif., April 15, 2011 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, today announced it has amended its tender offer related to its proposed acquisition of Cardiogenesis Corporation ("Cardiogenesis") to acquire only 49.9 percent of the outstanding shares of Cardiogenesis.  

On April 14, 2011, Cardiogenesis, CryoLife and CryoLife's wholly-owned subsidiary, CL Falcon, Inc., entered into an Amended and Restated Merger Agreement ("Agreement").  Pursuant to the Agreement, the tender offer has been revised to provide that CL Falcon, Inc. is offering to acquire only 49.9 percent of the outstanding shares of Cardiogenesis' common stock.  If more than 49.9 percent of the outstanding shares are tendered, CL Falcon, Inc. will purchase shares from the tendering shareholders on a prorated basis, as described in tender offer documents filed with the Securities and Exchange Commission ("SEC").  As a result of the Agreement, the Top-Up Option has been removed from the terms of the Offer and will no longer be effective.  The tender offer remains scheduled to expire at 12:00 midnight (one minute after 11:59 p.m.), New York City time, on the evening of May 2, 2011, unless extended.

Assuming that CryoLife acquires 49.9 percent of the outstanding shares of Cardiogenesis in the tender offer, Cardiogenesis will hold a special meeting of Cardiogenesis shareholders as soon as practical after the completion of the tender offer to vote on the proposed merger.  If more than 50 percent of the outstanding shares of Cardiogenesis, including those shares acquired by CryoLife in the tender offer, vote in favor of the merger, CryoLife and Cardiogenesis will move to complete the merger as soon as possible after the special meeting of Cardiogenesis shareholders.  Assu
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S.
2. David P. Lang Appointed Vice President of CryoLife International, Inc.
3. CryoLife to Present at UBS Global Life Sciences Conference
4. CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves
5. CryoLife to Present at UBS Global Life Sciences Conference
6. CryoLife Announces First Clinical Use of BioFoam(R)
7. CryoLifes Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
8. CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
9. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
10. CryoLife Reports Record First Quarter Revenues of $26.7 Million
11. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 6, 2015 ... von der Assistance Publique - Hôpitaux de ... ist eine französische, gemeinschaftliche, randomisierte Kontrollstudie für ... wurden. Verglichen werden Patienten mit fortgeschrittenem hepatozellulärem ... oder Sorafenib behandelt wurden. Die Ergebnisse werden ...
(Date:3/5/2015)... --  HX360 today announced that sixteen companies have ... Challenge competition. These companies, selected from a field ... one of four finalists to present their solutions live ... venture capitalists during the Innovation Challenge event. ... 2015 HIMSS Annual Conference & Exhibition, McCormick Place in ...
(Date:3/5/2015)... 05, 2015 BioPlus Specialty Pharmacy (BioPlus) ... of Vice President of Managed Care. In this role, ... one of the nation’s leading specialty pharmacies. , Damm, ... years of specialty pharmacy and biotech experience to his ... Pharmaceuticals, Vertex Pharmaceuticals, and Pfizer. Prior to working in ...
(Date:3/5/2015)... and TORONTO , March ... APS), a clinical-stage company developing new therapeutics and molecular ... announced that William G. Rice , Ph.D., Chairman, ... upcoming 27th Annual ROTH Conference on Tuesday, March 10 ... Ritz Carlton, Laguna Niguel, CA. ...
Breaking Biology Technology:Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3
... that Dr. Robert Harman, DVM, MPVM, CEO of Vet-Stem, ... of Action" at the Annual Research Symposium of the ... October 21, 2010.   (Logo: http://photos.prnewswire.com/prnh/20060425/VETSTEMLOGO ... Dr. Harman has presented at more than 40 veterinary ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, ... for its CYT387 JAK1/JAK2 inhibitor program demonstrating that ... profile which may provide significant clinical advantages. CYT387 ... clinical study at Mayo Clinic in patients with ...
... RALEIGH, NC and QUEBEC CITY, Oct. 1 /PRNewswire-FirstCall/ ... of Medicago Inc. (TSX: MDG), a biotechnology company ... based on proprietary manufacturing technologies and Virus-Like Particles ... U.S. Senator Kay Hagan (D-NC) and U.S. Congressman ...
Cached Biology Technology:Vet-Stem CEO to Present Invited Talk at Veterinary Surgery Meeting 2YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 2YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 3Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 2Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 3
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... N.C. , Feb. 5, 2015  Marken is ... logistics company and has launched a new marketing campaign ... Logistics Organization (CLO).  The new campaign focuses on ... patient, protocol and shipments. The first headline ... , aligns Marken,s priorities with its client,s priorities. Marken ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces the ... as part of its 2015 marketing and branding initiatives ... new consumer website for Wocketwallet.com earlier this month. ... said, "Our new corporate website naturally showcases our premiere ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... time, researchers have inhibited the development of epilepsy after a ... signaling pathways in the brain, neurology researchers found that they ... , "We have shown that there is a window ... that epilepsy will develop," said one of the lead researchers, ...
... Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ... that a single drug can rebuild damaged muscle in ... two human forms of muscular dystrophy. This advance, which ... from a research collaboration that began several years ago ...
... What is more, a newt can also completely repair damage ... Heart and Lung Research in Bad Nauheim have now started ... regenerate and have discovered the remarkable plasticity of newt heart ... this ability, the findings could contribute to new cell therapies ...
Cached Biology News:Gene therapy inhibits epilepsy in animals 2Scientists show drug can counteract muscular dystrophy in mice 2Newts which regrow their hearts 2
... DNA Polymerase I from ... DNA polymerase. The enzyme also ... activities.1 The 5'?3' exonuclease activity ... nicks and gaps in the ...
... E. coli strain containing an overproducing clone ... Reverse Transcriptase catalyzes the polymerization of DNA ... Full-length copies of large mRNAs, >10 kb, ... a much lower RNase H activity than ...
... catalyzes the template-directed polymerization of nucleotides into ... Polymerase I possesses a 3?5 exonuclease activity ... rate during DNA replication, and also contains ... enzyme to replace nucleotides in the growing ...
Request Info...
Biology Products: